Sex differences in schizophrenia

Last updated

Sex differences in schizophrenia are widely reported. [1] [2] [3] Men and women exhibit different rates of incidence and prevalence, age at onset, symptom expression, course of illness, and response to treatment. [2] [3] [4] Reviews of the literature suggest that understanding the implications of sex differences on schizophrenia may help inform individualized treatment and positively affect outcomes. [2] [5]

Contents

Incidence and prevalence

For both men and women, incidence of schizophrenia onset peaks at multiple points across the lifespan. [3] For men, the highest frequency of incidence onset occurs in the early twenties and there is evidence of a second peak in the mid-thirties. For women, there is a similar pattern with peaks in the early twenties and middle age. [6] Studies have also demonstrated a tertiary peak for women in the early sixties. Men have higher frequency rates of onset than women from the early twenties to middle age, and women have higher frequency rates of onset starting in late middle age. [7]

2005 and 2008 studies of prevalence rates of schizophrenia estimate that the lifetime likelihood of developing the disorder is 0.3–0.7%, and did not find evidence of sex differences. [8] [9] However, other studies have found a higher prevalence and severity in males than females. [1] [10] [3]

Clinical presentation

Symptom expression systematically differs between men and women. Women are more likely to experience high levels of depressive symptoms (i.e., low mood, anhedonia, fatigue) at illness onset and over the course of illness. [3] [6] Men are more likely to experience more negative symptoms than women at illness onset. There is conflicting evidence related to sex differences in the expression of positive symptoms. [3] [6] Some studies have found that women are more likely to experience positive symptoms. [11] [12] Other studies have found no significant sex differences in the expression of positive symptoms. [13] Younger age of onset is also related to earlier hospitalizations in men and more acute symptom severity in women. [14] [15]

Ties have been found between schizophrenic women's estrogen levels and their level of schizophrenia symptoms. [16] Such women have sometimes been found to benefit from hormonal treatment. Menstrual psychosis and postpartum psychosis may in some cases be linked to an underlying schizophrenic condition. [17] During a study conducted with a sample of 272 schizophrenia patients separated by four age groups and gender adults <35, 35–65, 65–80, >80 data was collected comparing specific schizophrenia symptoms and nonspecific symptoms seen in other psychiatric disorders. They used the BPRS (Brief Psychiatric Rating Scale) assessing (SANS) Scale for Assessment of Negative Symptoms and (SAPS) Scale for Assessment of Positive Symptoms. Where they gathered and provided data regarding the hypothesis of sex and age differences in symptoms and severity with schizophrenia. This study showed that men reflected higher severity of negative symptoms than women for all age groups (<35 and 35–65) except for the last two elderly (65-80 and >80) age groups, where women experience higher severity and more negative symptoms then men (Gur et al., 1996). This makes us wonder if the theory of decreased estrogen may be the cause of the second peak in women around menopause. It is known that women experience severe symptoms during low levels of estrogen for example during menstrual cycles. [18]

Differences course of illness and treatment outcomes

Course of illness and treatment outcomes

Longitudinal studies have found evidence of sex differences in presence of psychosis, global outcome, and recovery across periods of 15–20 years. [19] [20] [21] Several studies have demonstrated that women with schizophrenia are more likely to exhibit significantly greater reduction in psychotic symptoms, as well as better cognitive and global functioning relative to men. [19] [21] Additionally, studies have found that women are more likely to experience a period of recovery across the lifespan than men. [19] Further, there is consistent evidence of higher mortality rates, suicide attempts and completions, homelessness, poorer family and social support in men compared to women. [20] It is currently unclear the extent to which these observed differences can be attributed to age of onset.

Some studies demonstrate that age at illness onset likely contributes to observed sex differences in course of illness and treatment outcomes. [7] Increased negative and cognitive symptoms and poorer overall treatment outcomes are both related to younger age at onset, while fewer negative and cognitive symptoms are associated with older age at onset. [13] [19] These findings are consistent with the patterns of symptom expression observed in men and women and the relative age of onset for each gender. It is possible that men are more likely to experience poorer overall outcomes than women because of the relationship between younger age at onset and symptom severity. [3] However, some longitudinal studies have found that sex is a unique predictor of functional outcome over and above the effects of age. [19]

Differences in response to antipsychotic medications

Clinical trials examining sex differences in the efficacy of atypical antipsychotic medications found greater rates of symptom reduction in women compared to men. [22] However, women are at a greater risk for experiencing weight gain and developing metabolic syndrome as a result of antipsychotic medication use. [23] It is possible, however, that these differences in treatment response may be confounded by sex differences in clinical symptom severity and age at illness onset described above. [3]

Factors contributing to sex differences

Biological factors

The steroids and hormones associated with sex differentiation during fetal development have critical effects on neuronal development in humans, and there is evidence that these hormones have implications for sex differences in brain abnormalities observed in adults with schizophrenia. [3] MRI studies have revealed more severe brain damage in men diagnosed with schizophrenia than women. [24] Specifically, larger lateral and third ventricles and reduced volumes of critical regions such as the hippocampus, amygdala, and prefrontal cortical regions have been observed in men. [24] These brain abnormalities likely contribute to the observed short-term and long-term memory deficits in men diagnosed with schizophrenia. [25] It has been hypothesized that estrogen may serve a protective role in female development, buffering against the development of pervasive damage to this region. [26] [22] Further support for this hypothesis derives from the observation of a third peak of onset for women after menopause, which is associated with a reduction of estrogen, and the increased response to treatment in pre-menopausal women compared to post-menopausal women. [22] [27] Additionally, there is evidence that estradiol may be an effective adjunct to antipsychotic medication in reducing psychotic symptoms. [28]

Social and environmental factors

Social cognition and social functioning

Premorbid social functioning and social cognition, robust predictors of relapse in this population, differ significantly between men and women. [13] [29] Men have poorer overall premorbid social functioning and social cognition, which is associated with higher rates of isolation, loneliness, and lower quality of life. [29] [30] Social cognitive and functional deficits are also related to the increased expression of negative symptoms observed in men. [13] [19] Additionally, these factors are also associated with reduced social network size and lower marriage rates in men with schizophrenia compared to women. [4] Younger age at onset in men may also negatively impact community reintegration following the illness onset by delaying the development of life skills necessary to develop strong social support networks and foster self-perceptions of efficacy and agency. [30]

Substance abuse and dependence

Sex-related differences in substance use and dependence have been observed in individuals with schizophrenia and those at risk for developing the illness. In early adolescence, sex-related differences in cannabis use have been observed, with males using more heavily than females in the general population and in those at risk for developing schizophrenia. [31] There is evidence that these differences could in part be attributed to the predictive relationship between levels of testosterone in early adolescence and later cannabis use and dependence. [32] Frequent cannabis use in early adolescence may be a risk factor for developing schizophrenia in men. [33] There is some evidence that heavy, early cannabis use may be associated with impeded cortical maturation in males at a high risk for developing schizophrenia, potentially accelerating the course of illness in these individuals. [31]

Substance abuse is also highly correlated with poorer functional outcomes and can significantly influence the course of illness. Current research estimates that 36% of men have a history of illicit substance use versus 16% of women. [3] [34] Nicotine dependence is also highly prevalent in individuals with schizophrenia. An estimated 80% of individuals with schizophrenia smoke cigarettes compared to 20% of the general population. [35] Men with schizophrenia are more likely to start smoking than women, but social factors associated with mental illness contributing to increased rate of smoking in both genders. [36]

Related Research Articles

A mental disorder, also referred to as a mental illness, a mental health condition, or a psychiatric disorder, is a behavioral or mental pattern that causes significant distress or impairment of personal functioning. A mental disorder is also characterized by a clinically significant disturbance in an individual's cognition, emotional regulation, or behavior, often in a social context. Such disturbances may occur as single episodes, may be persistent, or may be relapsing–remitting. There are many different types of mental disorders, with signs and symptoms that vary widely between specific disorders. A mental disorder is one aspect of mental health.

Psychosis is a condition of the mind that results in difficulties determining what is real and what is not real. Symptoms may include delusions and hallucinations, among other features. Additional symptoms are incoherent speech and behavior that is inappropriate for a given situation. There may also be sleep problems, social withdrawal, lack of motivation, and difficulties carrying out daily activities. Psychosis can have serious adverse outcomes.

<span class="mw-page-title-main">Schizophrenia</span> Mental disorder with psychotic symptoms

Schizophrenia is a mental disorder characterized by reoccurring episodes of psychosis that are correlated with a general misperception of reality. Other common signs include hallucinations, delusions, disorganized thinking, social withdrawal, and flat affect. Symptoms develop gradually and typically begin during young adulthood and are never resolved. There is no objective diagnostic test; diagnosis is based on observed behavior, a psychiatric history that includes the person's reported experiences, and reports of others familiar with the person. For a diagnosis of schizophrenia, the described symptoms need to have been present for at least six months or one month. Many people with schizophrenia have other mental disorders, especially substance use disorders, depressive disorders, anxiety disorders, and obsessive–compulsive disorder.

Schizoaffective disorder is a mental disorder characterized by abnormal thought processes and an unstable mood. This diagnosis requires symptoms of both schizophrenia and a mood disorder: either bipolar disorder or depression. The main criterion is the presence of psychotic symptoms for at least two weeks without any mood symptoms. Schizoaffective disorder can often be misdiagnosed when the correct diagnosis may be psychotic depression, bipolar I disorder, schizophreniform disorder, or schizophrenia. This is a problem as treatment and prognosis differ greatly for most of these diagnoses.

<span class="mw-page-title-main">Tardive dyskinesia</span> Neurological disorder featuring involuntary, repetitive body movements

Tardive dyskinesia (TD) is a disorder that results in involuntary repetitive body movements, which may include grimacing, sticking out the tongue or smacking the lips. Additionally, there may be rapid jerking movements or slow writhing movements. In about 20% of people with TD, the disorder interferes with daily functioning. Reversibility of the condition is determined primarily by severity of symptoms and how long the condition has been present before stopping the offending drug.

Schizotypal personality disorder, also known as schizotypal disorder, is a cluster A personality disorder. The Diagnostic and Statistical Manual of Mental Disorders (DSM) classification describes the disorder specifically as a personality disorder characterized by thought disorder, paranoia, a characteristic form of social anxiety, derealization, transient psychosis, and unconventional beliefs. People with this disorder feel pronounced discomfort in forming and maintaining social connections with other people, primarily due to the belief that other people harbor negative thoughts and views about them. Peculiar speech mannerisms and socially unexpected modes of dress are also characteristic. Schizotypal people may react oddly in conversations, not respond, or talk to themselves. They frequently interpret situations as being strange or having unusual meanings for them; paranormal and superstitious beliefs are common. Schizotypal people usually disagree with the suggestion that their thoughts and behaviors are a 'disorder' and seek medical attention for depression or anxiety instead. Schizotypal personality disorder occurs in approximately 3% of the general population and is more commonly diagnosed in males.

Premenstrual dysphoric disorder (PMDD) is a mood disorder characterized by emotional, cognitive, and physical symptoms. PMDD causes significant distress or impairment in menstruating people during the luteal phase of the menstrual cycle. The symptoms occur in the luteal phase, improve within a few days after the onset of menses, and are minimal or absent in the week after menses. PMDD has a profound impact on a person's quality of life and dramatically increases the risk of suicidal ideation and even suicide attempts. Many women of reproductive age experience discomfort or mild mood changes prior to menstruation. However, 5–8% experience severe premenstrual syndrome causing significant distress or functional impairment. Within this population of reproductive age, some will meet the criteria for PMDD.

Sex differences in psychology are differences in the mental functions and behaviors of the sexes and are due to a complex interplay of biological, developmental, and cultural factors. Differences have been found in a variety of fields such as mental health, cognitive abilities, personality, emotion, sexuality, friendship, and tendency towards aggression. Such variation may be innate, learned, or both. Modern research attempts to distinguish between these causes and to analyze any ethical concerns raised. Since behavior is a result of interactions between nature and nurture, researchers are interested in investigating how biology and environment interact to produce such differences, although this is often not possible.

Thought broadcasting is a type of delusional condition in which the affected person believes that others can hear their inner thoughts, despite a clear lack of evidence. The person may believe that either those nearby can perceive their thoughts or that they are being transmitted via mediums such as television, radio or the internet. Different people can experience thought broadcasting in different ways. Thought broadcasting is most commonly found among people that have a psychotic disorder, specifically schizophrenia.

Gender is correlated with the prevalence of certain mental disorders, including depression, anxiety and somatic complaints. For example, women are more likely to be diagnosed with major depression, while men are more likely to be diagnosed with substance abuse and antisocial personality disorder. There are no marked gender differences in the diagnosis rates of disorders like schizophrenia and bipolar disorder. Men are at risk to suffer from post-traumatic stress disorder (PTSD) due to past violent experiences such as accidents, wars and witnessing death, and women are diagnosed with PTSD at higher rates due to experiences with sexual assault, rape and child sexual abuse. Nonbinary or genderqueer identification describes people who do not identify as either male or female. People who identify as nonbinary or gender queer show increased risk for depression, anxiety and post-traumatic stress disorder. People who identify as transgender demonstrate increased risk for depression, anxiety, and post-traumatic stress disorder.

Schizophrenia is a neurodevelopmental disorder with no precise or single cause. Schizophrenia is thought to arise from multiple mechanisms and complex gene–environment interactions with vulnerability factors. Risk factors of schizophrenia have been identified and include genetic factors, environmental factors such as experiences in life and exposures in a person's environment, and also the function of a person's brain at it develops. The interactions of these risk factors are intricate, as numerous and diverse medical insults from conception to adulthood can be involved. Many theories have been proposed including the combination of genetic and environmental factors may lead to deficits in the neural circuits that affect sensory input and cognitive functions.

Paradoxical laughter is an exaggerated expression of humour which is unwarranted by external events. It may be uncontrollable laughter which may be recognised as inappropriate by the person involved. It is associated with mental illness, such as mania, hypomania or schizophrenia, schizotypal disorder and can have other causes. Paradoxical laughter is indicative of an unstable mood, often caused by the pseudobulbar affect, which can quickly change to anger and back again, on minor external cues.

<span class="mw-page-title-main">Prevalence of mental disorders</span> The worldwide prevelance of mental health disorders.

The prevalence of mental disorders has been studied around the world, providing estimates on how common mental disorders are. Different criteria or thresholds of severity have sometimes been used.

Childhood schizophrenia is similar in characteristics of schizophrenia that develops at a later age, but has an onset before the age of 13 years, and is more difficult to diagnose. Schizophrenia is characterized by positive symptoms that can include hallucinations, delusions, and disorganized speech; negative symptoms, such as blunted affect and avolition and apathy, and a number of cognitive impairments. Differential diagnosis is problematic since several other neurodevelopmental disorders, including autism spectrum disorder, language disorder, and attention deficit hyperactivity disorder, also have signs and symptoms similar to childhood-onset schizophrenia.

<span class="mw-page-title-main">Prognosis of schizophrenia</span>

The prognosis of schizophrenia is varied at the individual level. In general it has great human and economics costs. It results in a decreased life expectancy of 12–15 years primarily due to its association with obesity, little exercise, and smoking, while an increased rate of suicide plays a lesser role. These differences in life expectancy increased between the 1970s and 1990s, and between the 1990s and 2000s. This difference has not substantially changed in Finland for example – where there is a health system with open access to care.

The diagnosis of schizophrenia, a psychotic disorder, is based on criteria in either the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, or the World Health Organization's International Classification of Diseases (ICD). Clinical assessment of schizophrenia is carried out by a mental health professional based on observed behavior, reported experiences, and reports of others familiar with the person. Diagnosis is usually made by a psychiatrist. Associated symptoms occur along a continuum in the population and must reach a certain severity and level of impairment before a diagnosis is made. Schizophrenia has a prevalence rate of 0.3-0.7% in the United States

<span class="mw-page-title-main">Epidemiology of schizophrenia</span>

Schizophrenia affects around 0.3–0.7% of people at some point in their life, or 21 million people worldwide as of 2020. By using precise methods in its diagnosis and a large, representative population, schizophrenia seems to occur with relative consistency over time during the last half-century.

Sex and gender differences in autism exist regarding prevalence, presentation, and diagnosis.

Schizophrenia is a mental disorder characterized by persistent hallucinations, delusions, paranoia, and thought disorder. These experiences are evident in multiple sensory modalities and include deviation in all facets of thought, cognition, and emotion. Compared to other psychological disorders like major depressive disorder (MDD) and generalized anxiety disorder (GAD), schizophrenia has significantly higher heritability. Schizophrenia has been found to present cross-culturally, and it almost always has 0.1% prevalence in a given population, although some studies have cast doubts on this. It has been hypothesized that schizophrenia is unique to human beings and has existed for a long time.

The male-female health-survival paradox, also known as the morbidity-mortality paradox or gender paradox, is the phenomenon in which female humans experience more medical conditions and disability during their lives, but they unexpectedly live longer than males. This paradox, where females experience greater morbidity (diseases) but lower mortality (death) in comparison to males, is unusual since it is expected that experiencing disease increases the likelihood of death. However, in this case, the part of the population that experiences more disease and disability is the one that lives longer.

References

  1. 1 2 McGrath, John; Saha, Sukanta; Chant, David; Welham, Joy (2008). "Schizophrenia: A Concise Overview of Incidence, Prevalence, and Mortality". Epidemiologic Reviews. 30: 67–76. doi: 10.1093/epirev/mxn001 . PMID   18480098. S2CID   2448141.
  2. 1 2 3 Aleman; Kahn; Selten (2003). "Sex differences in the risk of schizophrenia: evidence from meta-analysis". Archives of General Psychiatry. 60 (6): 565–71. doi: 10.1001/archpsyc.60.6.565 . PMID   12796219.
  3. 1 2 3 4 5 6 7 8 9 10 Abel, Kathryn; Drake, Richard; Goldstein, Jill (2010). "Sex differences in schizophrenia". International Review of Psychiatry. 22 (5): 417–428. doi:10.3109/09540261.2010.515205. PMID   21047156. S2CID   44933381.
  4. 1 2 Diagnostic and Statistical Manual of Mental Disorders. Arlington Virginia: American Psychological Association. 2013. ISBN   9780890425596.
  5. ↑ Lewine, Richard; Martin, Morgan; Hart, Mara (2017). "Sex versus gender differences in schizophrenia: The case for normal personality differences". Schizophrenia Research. 189: 57–60. doi:10.1016/j.schres.2017.02.015. PMC   5559345 . PMID   28215470.
  6. 1 2 3 Drake, Richard J.; Addington, Jean; Viswanathan, Ananth C.; Lewis, Shôn W.; Cotter, Jack; Yung, Alison R.; Abel, Kathryn M. (2016-02-16). "How Age and Gender Predict Illness Course in a First-Episode Nonaffective Psychosis Cohort". The Journal of Clinical Psychiatry. 77 (3): e283–e289. doi:10.4088/jcp.14m09369. ISSN   0160-6689. PMID   26890690.
  7. 1 2 Castle, David J.; Wessely, Simon; Murray, Robin M. (May 1993). "Sex and Schizophrenia: Effects of Diagnostic Stringency, and Associations with Premorbid Variables". British Journal of Psychiatry. 162 (5): 658–664. doi:10.1192/bjp.162.5.658. ISSN   0007-1250. PMID   8149118. S2CID   15183952.
  8. ↑ McGrath, J.; Saha, S.; Chant, D.; Welham, J. (2008-05-14). "Schizophrenia: A Concise Overview of Incidence, Prevalence, and Mortality". Epidemiologic Reviews. 30 (1): 67–76. doi: 10.1093/epirev/mxn001 . ISSN   0193-936X. PMID   18480098.
  9. ↑ Saha, Sukanta; Chant, David; Welham, Joy; McGrath, John (2005-05-31). "A Systematic Review of the Prevalence of Schizophrenia". PLOS Medicine. 2 (5): e141. doi: 10.1371/journal.pmed.0020141 . ISSN   1549-1676. PMC   1140952 . PMID   15916472.
  10. ↑ Aleman; Kahn; Selten (2003). "Sex differences in the risk of schizophrenia: evidence from meta-analysis". Archives of General Psychiatry. 60 (6): 565–71. doi: 10.1001/archpsyc.60.6.565 . PMID   12796219.
  11. ↑ Goldstein, Jill M.; Link, Bruce G. (January 1988). "Gender and the expression of schizophrenia". Journal of Psychiatric Research. 22 (2): 141–155. doi:10.1016/0022-3956(88)90078-7. ISSN   0022-3956. PMID   3404482.
  12. ↑ Cheng, C.Z.; Wu Qianjin (February 1994). "Population Aging in China: The Demographic Implications". China Report. 30 (1): 29–51. doi:10.1177/000944559403000103. ISSN   0009-4455. S2CID   153662106.
  13. 1 2 3 4 Morgan, Vera A.; Castle, David J.; Jablensky, Assen V. (January 2008). "Do Women Express and Experience Psychosis Differently from Men? Epidemiological Evidence from the Australian National Study of Low Prevalence (Psychotic) Disorders". Australian & New Zealand Journal of Psychiatry. 42 (1): 74–82. doi:10.1080/00048670701732699. ISSN   0004-8674. PMID   18058447. S2CID   23224974.
  14. ↑ Häfner, H.; Riecher, A.; Maurer, K.; Löffler, W.; Munk-Jørgensen, P.; Strömgren, E. (2009). "How does gender influence age at first hospitalization for schizophrenia? A transnational case register study". Psychological Medicine. 19 (4): 903–918. doi:10.1017/S0033291700005626. PMID   2594886. S2CID   19340641.
  15. ↑ Angermeyer, M. C.; Kühn, L. (1988). "Gender differences in age at onset of schizophrenia. An overview". European Archives of Psychiatry and Neurological Sciences. 237 (6): 351–364. doi:10.1007/BF00380979. PMID   3053193. S2CID   1001928.
  16. ↑ Grigoriadis, Sophie; Seeman, Mary V. (2002). "The Role of Estrogen in Schizophrenia: Implications for Schizophrenia Practice Guidelines for Women". The Canadian Journal of Psychiatry. 47 (5): 437–442. doi: 10.1177/070674370204700504 . PMID   12085678.
  17. ↑ Gogos, Andrea; Sbisa, Alyssa M.; Sun, Jeehae; Gibbons, Andrew; Udawela, Madhara; Dean, Brian (2015). "A Role for Estrogen in Schizophrenia: Clinical and Preclinical Findings". International Journal of Endocrinology. 2015: 1–16. doi: 10.1155/2015/615356 . PMC   4600562 . PMID   26491441.
  18. ↑ Gur, Raquel E.; Petty, Richard G.; Turetsky, Bruce I.; Gur, Ruben C. (July 1996). "Schizophrenia throughout life: sex differences in severity and profile of symptoms". Schizophrenia Research. 21 (1): 1–12. doi: 10.1016/0920-9964(96)00023-0 .
  19. 1 2 3 4 5 6 Grossman, Linda S.; Harrow, Martin; Rosen, Cherise; Faull, Robert; Strauss, Gregory P. (November 2008). "Sex differences in schizophrenia and other psychotic disorders: a 20-year longitudinal study of psychosis and recovery". Comprehensive Psychiatry. 49 (6): 523–529. doi:10.1016/j.comppsych.2008.03.004. ISSN   0010-440X. PMC   2592560 . PMID   18970899.
  20. 1 2 Conwell, Yeates; Chen, Eric Yu-Hai; Chan, Cecilia Lai-Wan; Mao, Wen-Jun; Ran, Mao-Sheng (April 2015). "Gender differences in outcomes in people with schizophrenia in rural China: 14-year follow-up study". The British Journal of Psychiatry. 206 (4): 283–288. doi:10.1192/bjp.bp.113.139733. ISSN   1472-1465. PMC   4381189 . PMID   25573398.
  21. 1 2 Bergh, Sara; Hjorthøj, Carsten; Sørensen, Holger J.; Fagerlund, Birgitte; Austin, Stephen; Secher, Rikke Gry; Jepsen, Jens Richardt; Nordentoft, Merete (August 2016). "Predictors and longitudinal course of cognitive functioning in schizophrenia spectrum disorders, 10 years after baseline: The OPUS study". Schizophrenia Research. 175 (1–3): 57–63. doi:10.1016/j.schres.2016.03.025. ISSN   0920-9964. PMID   27050475. S2CID   3151870.
  22. 1 2 3 Goldstein, Jill M.; Cohen, Lee S.; Horton, Nicholas J.; Lee, Hang; Andersen, Scott; Tohen, Mauricio; Crawford, Ann-Marie K.; Tollefson, Gary (May 2002). "Sex differences in clinical response to olanzapine compared with haloperidol". Psychiatry Research. 110 (1): 27–37. doi:10.1016/s0165-1781(02)00028-8. ISSN   0165-1781. PMID   12007591. S2CID   25470846.
  23. ↑ Goff, Donald C.; Sullivan, Lisa M.; McEvoy, Joseph P.; Meyer, Jonathan M.; Nasrallah, Henry A.; Daumit, Gail L.; Lamberti, Steven; D'Agostino, Ralph B.; Stroup, Thomas S. (December 2005). "A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls". Schizophrenia Research. 80 (1): 45–53. doi:10.1016/j.schres.2005.08.010. ISSN   0920-9964. PMID   16198088. S2CID   21196294.
  24. 1 2 Flaum, M.; Swayze Vw, 2nd; O'Leary, D. S.; Yuh, W. T.; Ehrhardt, J. C.; Arndt, S. V.; Andreasen, N. C. (May 1995). "Effects of diagnosis, laterality, and gender on brain morphology in schizophrenia". American Journal of Psychiatry. 152 (5): 704–714. doi:10.1176/ajp.152.5.704. ISSN   0002-953X. PMID   7726310.{{cite journal}}: CS1 maint: numeric names: authors list (link)
  25. ↑ Han, M.; Huang, X. F.; Chen, D. C.; Xiu, M. H.; Hui, L.; Liu, H.; Kosten, T. R.; Zhang, X. Y. (2012). "Gender differences in cognitive function of patients with chronic schizophrenia". Progress in Neuro-Psychopharmacology and Biological Psychiatry. 39 (2): 358–363. doi:10.1016/j.pnpbp.2012.07.010. PMID   22820676. S2CID   6021327.
  26. ↑ Häfner, H (2003). "Gender differences in schizophrenia". Psychoneuroendocrinology. 28: 17–54. doi:10.1016/s0306-4530(02)00125-7. PMID   12650680. S2CID   9307284.
  27. ↑ Castle D, Sham P, Murray R. (1998). "Differences in distribution of ages of onset in males and females with schizophrenia". Schizophrenia Research. 33 (3): 179–183. doi:10.1016/s0920-9964(98)00070-x. PMID   9789910. S2CID   22355423.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  28. ↑ Kulkarni J, Riedel A, de Castella AR; et al. (2001). "Estrogen – A potential treatment for schizophrenia". Schizophrenia Research. 48 (1): 137–144. doi:10.1016/s0920-9964(00)00088-8. PMID   11278160. S2CID   42146691.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  29. 1 2 Ritsner, Michael S.; Arbitman, Marina; Lisker, Alexander; Ponizovsky, Alexander M. (2011-10-02). "Ten-year quality of life outcomes among patients with schizophrenia and schizoaffective disorder II. Predictive value of psychosocial factors". Quality of Life Research. 21 (6): 1075–1084. doi:10.1007/s11136-011-0015-4. ISSN   0962-9343. PMID   21964946. S2CID   8413911.
  30. 1 2 Howes, Oliver D; Murray, Robin M (May 2014). "Schizophrenia: an integrated sociodevelopmental-cognitive model". The Lancet. 383 (9929): 1677–1687. doi:10.1016/s0140-6736(13)62036-x. ISSN   0140-6736. PMC   4127444 . PMID   24315522.
  31. 1 2 Paus, Tomáš; Pausova, Zdenka; Smith, George Davey; Schumann, Gunter; Timpson, Nic J.; Whelan, Robert; Walter, Henrik; Smolka, Michael N.; Rietschel, Marcella (2015-10-01). "Early Cannabis Use, Polygenic Risk Score for Schizophrenia and Brain Maturation in Adolescence". JAMA Psychiatry. 72 (10): 1002–1011. doi:10.1001/jamapsychiatry.2015.1131. ISSN   2168-622X. PMC   5075969 . PMID   26308966.
  32. ↑ Tarter, Ralph E.; Kirisci, Levent; Gavaler, Judith S.; Reynolds, Maureen; Kirillova, Galina; Clark, Duncan B.; Wu, Jionglin; Moss, Howard B.; Vanyukov, Michael (January 2009). "Prospective Study of the Association Between Abandoned Dwellings and Testosterone Level on the Development of Behaviors Leading to Cannabis Use Disorder in Boys". Biological Psychiatry. 65 (2): 116–121. doi:10.1016/j.biopsych.2008.08.032. ISSN   0006-3223. PMC   2643094 . PMID   18930183.
  33. ↑ Manrique-Garcia, E.; Zammit, S.; Dalman, C.; Hemmingsson, T.; Andreasson, S.; Allebeck, P. (2011-10-17). "Cannabis, schizophrenia and other non-affective psychoses: 35 years of follow-up of a population-based cohort". Psychological Medicine. 42 (6): 1321–1328. doi:10.1017/s0033291711002078. ISSN   0033-2917. PMID   21999906. S2CID   34537539.
  34. ↑ Jablensky, Assen; McGrath, John; Herrman, Helen; Castle, David; Gureje, Oye; Evans, Mandy; Carr, Vaughan; Morgan, Vera; Korten, Ailsa (April 2000). "Psychotic Disorders in Urban Areas: An Overview of the Study on Low Prevalence Disorders". Australian & New Zealand Journal of Psychiatry. 34 (2): 221–236. doi:10.1080/j.1440-1614.2000.00728.x. ISSN   0004-8674. PMID   10789527. S2CID   41541983.
  35. ↑ Keltner, N. L.; Grant, J. S. (2006). "Smoke, Smoke, Smoke That Cigarette". Perspectives in Psychiatric Care. 42 (4): 256–261. doi:10.1111/j.1744-6163.2006.00085.x. PMID   17107571.
  36. ↑ Gur, R. E.; Petty, R. G.; Turetsky, B.I.; Gur, R.C. (1996). "Schizophrenia throughout life: sex differences in severity and profile of symptoms". Schizophrenia Research. 21 (1): 1–12. doi: 10.1016/0920-9964(96)00023-0 .
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.